2019 nCoV (SARS CoV2 coronavirus) Spike(S1+S2)- RBD N501Y mutation (B.1.1.7 lineage RBD) pcDNA3.1(+) vector

Cat No.:GMV-V-2019nCoV-101

Order information

Package Catalog No. Price(In USD) Qty (Quantity) Sum(In USD)
5ug GMV-V-2019nCoV-101 1890
Shipping Cost: 169.00


2019 nCoV related GeneSpike(S1+S2)-RBD N501Y mutation(B.1.1.7 lineage RBD)
Species HostSARS-COV-2 B.1.1.7 lineage
Antibiotic in Mammalian cellNeomycin / G418
TagNo tag
Codon OptimizedCodon Optimized for mamamlian

SARS-CoV-2 spike-N501Y mutation

The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. Most mutations and deletions of SARS-CoV-2 occur in the coronavirus spike protein. Spike position N501, one of the key contact residues in the receptor-binding domain (RBD), and experimental data suggest mutation N501Y can increase ACE2 receptor affinity (Starr et al. 2020). N501Y has also been associated with increased infectivity and virulence in a mouse model (Gu et al. 2020).

Recently a novel SARS-COV-2 (2019nCOV) lineage, the B.1.1.7 lineage, with serials of site mutation, shows stronger infection ability in the UK. In SARS-COV-2 B.1.1.7 lineage, most mutations and deletions occur in the coronavirus spike protein. These mutantions also include SARS-CoV-2 spike-mutation. N501Y mutation is also found in the South Africa 501Y.V2 lineage.

The pre-made gene ORF vector of Spike(S1+S2)-N501Y mutation is Codon Optimized for mamamlian and can be used for mammalian expression.

GeneMedi also provides pre-made the lentivirus, adenovirus and AAV vector for the gene ORF plasmids of 2019 nCoV (SARS2 coronavirus).

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Spike-N501Y mutation

Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-N501Y mutation, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) spike-N501Y mutation

GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) spike-N501Y mutation

Gu, Hongjing, Qi Chen, Guan Yang, Lei He, Hang Fan, Yong-Qiang Deng, Yanxiao Wang, et al. 2020. “Adaptation of SARS-CoV-2 in BALB/c Mice for Testing Vaccine Efficacy.” Science 369 (6511): 1603–7.

Starr, Tyler N., Allison J. Greaney, Sarah K. Hilton, Daniel Ellis, Katharine H. D. Crawford, Adam S. Dingens, Mary Jane Navarro, et al. 2020. “Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.” Cell 182 (5): 1295–1310.e20.